Cancer
Malignant Gastric Neoplasm
CI-CAN-00001130Explore in graph →
Top-level650 active trials4 approved drugs55 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00001130Explore in graph →
Clinical trials
2,844 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (232)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04260802 | A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers | terminated | Phase 1 / Phase 2 | 73 | Ocellaris Pharma, Inc.INDUSTRY | 1 | Jan 12, 2026 | clinicaltrials |
| NCT07332533 | A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer | not yet recruiting | Phase 2 / Phase 3 | 490 | Shanghai JMT-Bio Inc.INDUSTRY | 0 | Jan 12, 2026 | clinicaltrials |
| NCT07333573 | A Hypoxia-Inducible CAR-T Cell Targeting AXL and CD73 for Advanced Gastric Cancer | not yet recruiting | Phase 1 / Phase 2 | 42 | Shanghai Zhongshan HospitalOTHER | 1 | Jan 12, 2026 | clinicaltrials |
| NCT07334431 | Fruquintinib Combined With Trastuzumab and XELOX as First-line Treatment in Patients With HER2-positive Advanced Gastric Cancer | recruiting | Phase 1 / Phase 2 | 45 | Henan Cancer HospitalOTHER_GOV | 1 | Jan 12, 2026 | clinicaltrials |
| NCT07110571 | A Trial of Adebrelimab Plus (SHR-A1811/SHR-A1904 With Chemotherapy) or SHR-8068 as Treatment for Gastric/GEJ Cancer | recruiting | Phase 2 | 200 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Jan 9, 2026 | clinicaltrials |
| NCT07315854 | Iparomlimab and Tuvonralimab (QL1706) Combined With Chemotherapy for Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer | recruiting | Phase 2 | 32 | Beijing Friendship HospitalOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT07315035 | QL1706-SOX vs SOX Alone as Neoadjuvant Therapy for Resectable Diffuse-Type Gastric Cancer | not yet recruiting | Phase 2 | 74 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT07311408 | SHR-1701 + Rivoceranib (± SHR-2554) in Advanced GC After First-Line Immunotherapy Failure(SHR-2554) | recruiting | Phase 2 | 40 | Jingdong ZhangOTHER | 1 | Dec 31, 2025 | clinicaltrials |
| NCT05898854 | [68Ga]Ga-FAPI PET/CT in Gastric and Gastroesophageal Junctional Cancer | completed | Phase 2 | 20 | Aalborg University HospitalOTHER | 1 | Dec 30, 2025 | clinicaltrials |
| NCT07283848 | Zimberelimab + Domvanalimab in Gastroesophageal Adenocarcinoma | withdrawn | Phase 2 | 0 | Massachusetts General HospitalOTHER | 1 | Dec 26, 2025 | clinicaltrials |
| NCT07289997 | Iparomlimab and Tuvonralimab Combined With Apatinib and Irinotecan Hydrochloride for the Treatment of Advanced Alpha-fetoprotein-producing Gastric Cancer (AFPGC) | recruiting | Phase 2 | 39 | Hebei Medical University Fourth HospitalOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT05419362 | GEN-001 in Combination With Avelumab for Patients With PD-L1 Positive Gastric Cancer | completed | Phase 2 | 42 | Genome & CompanyINDUSTRY | 1 | Dec 16, 2025 | clinicaltrials |
| NCT04798781 | Safety and Efficacy of Telatinib in Combination With Keytruda in Subjects With Advanced Stomach and Gastroesophageal Junction Cancers or Hepatocellular Carcinoma | completed | Phase 2 | 16 | Andrew Hendifar, MDOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT06943521 | A Study of MT-4561 in Patients With Various Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 27 | Tanabe Pharma America, Inc.INDUSTRY | 2 | Dec 11, 2025 | clinicaltrials |
| NCT07263386 | A Phase II, Multicenter, Randomized, Controlled Clinical Study Comparing the Efficacy and Safety of Sintilimab Plus SOX Versus SOX Alone as Adjuvant Therapy for PD-L1-Positive, Stage pN3 Gastric Cancer(ARTEMIS-GC3) | recruiting | Phase 2 | 460 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT06333314 | Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI(Pan-MSI-ACSE) | recruiting | Phase 2 | 120 | UNICANCEROTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT07257575 | A Randomized Controlled Study of Serplulimab Combined With Chemotherapy for Locally Advanced Gastric Adenocarcinoma | active not recruiting | Phase 2 | 138 | Guangdong Provincial People's HospitalOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT07259226 | Optimal Methods to Characterize ADC Resistance in Solid Tumors and Identify Clinically Useful Biomarkers(OASIS) | recruiting | Phase 2 | 400 | UNICANCEROTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT04779151 | Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab(NIRADO) | terminated | Phase 2 | 51 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Dec 1, 2025 | clinicaltrials |
| NCT06988475 | DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT06313801 | Comparing the Safety and Efficacy of First-line Polychemotherapy and Polychemotherapy in Combination With PIPAC Sessions | recruiting | Phase 2 | 106 | Nizhny Novgorod Regional Clinical Oncology CenterOTHER_GOV | 1 | Nov 21, 2025 | clinicaltrials |
| NCT07149090 | Lenvatinib in Combination With Nivolumab Plus Chemotherapy in Metastatic Gastric Cancer Patients With Malignant Ascites | recruiting | Phase 1 / Phase 2 | 61 | Asan Medical CenterOTHER | 1 | Nov 20, 2025 | clinicaltrials |
| NCT06759064 | Intraperitoneal Immune Checkpoint Inhibitors and Zoledronic Acids for Gastric Cancer Malignant Ascites(IPIZA) | recruiting | Phase 1 / Phase 2 | 24 | Qilu Hospital of Shandong UniversityOTHER | 1 | Nov 19, 2025 | clinicaltrials |
| NCT04504916 | A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002) | terminated | Phase 2 | 102 | VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 2 | Nov 10, 2025 | clinicaltrials |
| NCT06487221 | Avutometinib and Defactinib in Diffuse Gastric Cancer | recruiting | Phase 2 | 27 | Ryan H. Moy, MD, PhDOTHER | 1 | Nov 4, 2025 | clinicaltrials |
| NCT01191697 | CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer | completed | Phase 2 | 37 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 3, 2025 | clinicaltrials |
| NCT03620643 | Crizotinib in Lobular Breast, Diffuse Gastric and Triple Negative Lobular Breast Cancer or CDH1-mutated Solid Tumours(ROLo) | completed | Phase 2 | 33 | Royal Marsden NHS Foundation TrustOTHER | 1 | Oct 30, 2025 | clinicaltrials |
| NCT05205330 | Vorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractory pMMR - MSS CRC, and Other Metastatic GI Cancers | active not recruiting | Phase 1 / Phase 2 | 107 | Rottapharm BiotechINDUSTRY | 1 | Oct 29, 2025 | clinicaltrials |
| NCT04208958 | Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer(ConsortiumIO) | completed | Phase 1 / Phase 2 | 56 | Vedanta Biosciences, Inc.INDUSTRY | 1 | Oct 27, 2025 | clinicaltrials |
| NCT04363801 | A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal Cancer(DisTinGuish) | terminated | Phase 2 | 247 | Leap Therapeutics, Inc.INDUSTRY | 3 | Oct 9, 2025 | clinicaltrials |
| NCT04931654 | A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer | active not recruiting | Phase 1 / Phase 2 | 136 | AstraZenecaINDUSTRY | 10 | Oct 9, 2025 | clinicaltrials |
| NCT07212933 | The Safety and Clinical Efficacy of RAK Cell Therapy in Late-stage Gastric Cancer: A Randomized Controlled Trial(RAK in GC) | recruiting | Phase 2 | 90 | Chinese PLA General HospitalOTHER | 1 | Oct 8, 2025 | clinicaltrials |
| NCT00722228 | Autologous and Allogeneic Whole Cell Cancer Vaccine for Metastatic Tumors | recruiting | Phase 1 / Phase 2 | 50 | Hadassah Medical OrganizationOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT05177068 | Conversion Therapy of Fruquintinib in Combination With Sintilimab and SOX in Unresectable Gastric Cancer | active not recruiting | Phase 2 | 42 | Henan Cancer HospitalOTHER_GOV | 1 | Oct 2, 2025 | clinicaltrials |
| NCT05980481 | A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer | active not recruiting | Phase 2 / Phase 3 | 201 | RemeGen Co., Ltd.INDUSTRY | 1 | Sep 29, 2025 | clinicaltrials |
| NCT06008054 | A Study of SI-B003, BL-B01D1+SI-B003 and BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric Cancer, Colorectal Cancer and Other Gastrointestinal Tumors | recruiting | Phase 2 | 376 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 26, 2025 | clinicaltrials |
| NCT07194005 | Conversion Therapy With RC48, Sintilimab, and SOX for HER2 1+/2+ Unresectable Gastric Cancer(Remission) | recruiting | Phase 2 | 30 | Fudan UniversityOTHER | 1 | Sep 26, 2025 | clinicaltrials |
| NCT04768686 | FLX475 Combined With Pembrolizumab in Patients With Advanced or Metastatic Gastric Cancer | completed | Phase 2 | 20 | Hanmi Pharmaceutical Company LimitedINDUSTRY | 1 | Sep 25, 2025 | clinicaltrials |
| NCT06253611 | First-line EXL01 With Nivolumab and FOLFOX for PD-L1 CPS ≥5 Metastatic Gastric Cancer(BIG) | recruiting | Phase 2 | 120 | GERCOR - Multidisciplinary Oncology Cooperative GroupOTHER | 1 | Sep 22, 2025 | clinicaltrials |
| NCT05632939 | ASKB589 in Combination With CAPOX and PD-1 Inhibitors in Patients With Advanced, and Unresectable G/GEJ Cancer. | active not recruiting | Phase 1 / Phase 2 | 62 | AskGene Pharma, Inc.INDUSTRY | 1 | Sep 10, 2025 | clinicaltrials |
| NCT07102901 | Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma | recruiting | Phase 2 | 351 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Sep 10, 2025 | clinicaltrials |
| NCT07165847 | Neoadjuvant Radiotherapy Plus Tegafur, Oxaliplatin and Iparomlimab and Tuvonralimab in Resectable Gastric and GE-junction Cancer : A Randomized, Two-arm, Prospective Trial (TRIUNITE-05) | recruiting | Phase 2 | 40 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER | 1 | Sep 10, 2025 | clinicaltrials |
| NCT07018661 | [18F]F-FAPI PET/CT and Laparoscopy in Staging Advanced Gastric Cancer(PLASTIC-3) | recruiting | Phase 2 / Phase 3 | 250 | Leiden University Medical CenterOTHER | 1 | Aug 27, 2025 | clinicaltrials |
| NCT07144657 | Prospective Study of Frontline Antibiotics Therapy in the Treatment of Early-stage HP-negative Gastric MALT Lymphoma(GastricMALToma) | not yet recruiting | Phase 2 | 40 | National Taiwan University HospitalOTHER | 1 | Aug 27, 2025 | clinicaltrials |
| NCT05259696 | Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)(GLIMMER-01) | completed | Phase 1 / Phase 2 | 69 | Palleon Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 20, 2025 | clinicaltrials |
| NCT07119463 | Effect of Goal-Oriented Albumin Infusion on Postoperative Complication Management in Gastric Cancer Surgery(GOAI) | recruiting | Phase 2 | 112 | The First Hospital of Jilin UniversityOTHER | 1 | Aug 13, 2025 | clinicaltrials |
| NCT06298916 | 64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer(PHANTOM) | recruiting | Phase 1 / Phase 2 | 26 | Lantheus Medical ImagingINDUSTRY | 1 | Aug 12, 2025 | clinicaltrials |
| NCT05057013 | A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours | active not recruiting | Phase 1 / Phase 2 | 81 | Cancer Research UKOTHER | 1 | Aug 11, 2025 | clinicaltrials |
| NCT05002127 | A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06) | active not recruiting | Phase 2 / Phase 3 | 127 | ALX Oncology Inc.INDUSTRY | 12 | Aug 7, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Jan 12, 2026source: clinicaltrials